Jubilant Life Sciences Ltd - 530019 - Announcement under Regulation 30 (LODR)-Credit Rating
Dear Sirs, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that CRISIL Limited has assigned ratings to the Company's Rs. 350 Crore Non-Convertible Debentures and Rs. 400 Crore Commercial Paper Programme by its letter dated October 31, 2019 as per the attached document. This is for your kind information and record. JUBILANT LIFE SCIENCES LIMITED - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation of our letter dated October 25, 2019, we enclose copies of the Unaudited Consolidated Financial Results for the quarter ended September 30, 2019 published on October 26, 2019 in MINT (English) and HINDUSTAN (Hindi).
Jubilant Life to create separate firms for pharma, life science operations
Jubilant Life's consolidated pharmaceutical entity generate revenue of 5,567 crore in 2018-19.The board also accepted another recommendation made by the committee, of amalgamating the promoter shareholding companies into Jubilant Life Jubilant Life Sciences Ltd - 530019 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the disclosure pertaining to approval of the Composite Scheme of Arrangement by the Board of Directors of the Company at its meeting held on October 25, 2019. Jubilant Life Sciences Ltd - 530019 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regarding Slump Sale Of India Branded Pharmaceuticals Business To A Wholly Owned Indirect Subsidiary
Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the disclosure pertaining to sale of India Branded Pharmaceuticals Business of the Company to Jubilant Generics Limited, a wholly-owned indirect subsidiary of the Company. The same has been approved by the Board at its meeting held on October 25, 2019. Relevant details are given in Annexure-A. Jubilant Life Sciences Ltd - 530019 - Compliance With Regulation 52(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
We enclose a certificate dated October 25, 2019 received from Vistra ITCL (India) Limited, Debenture Trustee, pursuant to Regulation 52 (5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Non-Convertible Debentures of the Company listed on National Stock Exchange of India Limited. We request you to take the same on records. JUBILANT LIFE SCIENCES LIMITED - 530019 - Announcement under Regulation 30 (LODR)-Change in Management
We wish to inform about the following changes in the Key Management Personnel: Mr. Sankaraiah Rajagopal, Executive Director-Finance and Key Managerial Personnel will be superannuating from the services of the Company on March 31, 2020 and shall continue to be an advisor to the Group. The Board has, at its meeting held today, approved the appointment of Mr. Alok Vaish as Chief Financial Officer and Key Management Personnel of the Company effective from April 1, 2020. Mr. Vaish has joined the Company effective today as Chief Financial Officer Designate. Mr. Vaish, 50 years, is a qualified Chartered Accountant and Company Secretary with an MBA degree from University of Virginia, USA, with over 24 years of experience in the areas of fund raising, mergers & acquisitions, financial planning, budgeting, cash-flow management, investor relations, legal and corporate secretarial functions and administration. This is for your information and records. Jubilant Life Sciences Ltd - 530019 - Results For The Quarter And Half Year Ended September 30, 2019
In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended September 30, 2019 were approved by the Board of Directors of the Company at its meeting held today at 1.00 p.m. and concluded at 3.40 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended September 30, 2019; 2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter; and 3. Copies of the Press Release and Presentation. We request you to take the same on records. JUBILANT LIFE SCIENCES LIMITED - 530019 - Results For The Quarter And Half Year Ended September 30, 2019
In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended September 30, 2019 were approved by the Board of Directors of the Company at its meeting held today at 1.00 p.m. and concluded at 3.40 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended September 30, 2019; 2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter; and 3. Copies of the Press Release and Presentation. We request you to take the same on records. Jubilant Life Sciences Ltd - 530019 - Certificate Obtained From A Practising Company Secretary For The Period Ended September 30, 2019
As per Regulation 40(9) and Regulation 40(10) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a Certificate obtained from a Practising Company Secretary for the period ended September 30, 2019.